NCT03585270: A reported trial by Idorsia Pharmaceuticals Ltd.
This trial has reported on time, in line with the regulations.
Full data
Full entry on ClinicalTrials.gov | NCT03585270 |
---|---|
Title | A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH) |
Results Status | Reported |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | Feb. 3, 2019 |
Completion date | June 13, 2022 |
Required reporting date | June 13, 2025, midnight |
Actual reporting date | Nov. 14, 2023 |
Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
Days late | None |